Background
Materials and methods
Cell lines
Western blotting
Histological samples
Cytological samples
Claspin immunostaining
HPV testing
Statistical analyses
Results
In vitro claspin expression
Claspin expression in human cervical lesions
Histology | Claspin-positive nuclei/HPF | |
---|---|---|
Mean (±SD) | Median (Min-Max) | |
WNL (n = 9) | 0.4 (±0.8) | 0.0 (0.0 -1.8) |
CIN1 (n = 19) | 7.4 (±13.8) | 0.0 (0.0 -51.5) |
CIN2 (n = 21) | 46.8 (±38.8) | 36.5 (1.0-148.6) |
CIN3 (n = 16) | 72.6 (±46.7) | 67.3 (2.0-159.1) |
SCC (n = 15) | 133.9 (±75.8) | 200.0 (11.8-200.0) |
Correlation between claspin immunoreactivity and HR-HPV infection
Claspin expression n (%) | HR-HPV n (%) | WNL n = 9 | CIN1 n = 19 | CIN2 n = 21 | CIN3 n = 16 | SCC n = 15 |
---|---|---|---|---|---|---|
Negative/Low33 (41.2) | Negative 10 (30.3) | 5 | 5 | \ | \ | \ |
Positive 23 (69.7) | 4 | 11 | 5 | 2 | 1 | |
Moderate/High47 (58.8) | Negative 1 (2.2) | \ | 1 | \ | \ | \ |
Positive 46 (97.8) | \ | 2 | 16 | 14 | 14 |
HPV genotyping | Claspin expression | ||
---|---|---|---|
Negative/Low | Moderate/High | Total | |
HPV 16/18 positive* | 8 (27%) | 22 (73%) |
30 (100%)
|
HR-HPV positive† | 9 (36%) | 16 (64%) |
25 (100%)
|
Total | 17 (31%) | 38 (69%) | 55 (100%) |
Claspin expression in cervical cytology
Claspin expressionn (%) | HR-HPV n (%) | NILM n = 3 | L-SIL n = 7 | H-SIL n = 9 |
---|---|---|---|---|
Negative 5 (26.3) | Negative 3 (60.0) | 2 | 1 | \ |
Positive 2 (40.0) | \ | 2 | \ | |
Positive14 (73.7) | Negative 0 (0.0) | \ | \ | \ |
Positive 14 (100) | 1 | 4 | 9 |